Cefepime

Revision as of 02:41, 26 December 2013 by Gerald Chi (talk | contribs)
Jump to navigation Jump to search
Cefepime
MAXIPIME® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings
Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
Compatibility, Reconstitution, and Stability
Directions for Use
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cefepime (INN) (IPA: Template:IPA) is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both Gram-negative and Gram-positive organisms than third-generation agents. Cefepime hydrochloride was first marketed in 1994 and is currently marketed under various trade names includingMaxipime (Elan Pharma), Maxcef, Cepimax, Cepimex, and Axepim.

Category

Cephalosporin, Fourth-Generation

US Brand Names

MAXIPIME®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Other Size Packages Available | Labels and Packages

Mechanisms of Action

References